Company Profile
OpGen Stock Price, News & Analysis
- Ticker:
- OPGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for OPGN.
Company overview
Business overview
OpGen was a molecular diagnostics company focused on infectious disease and rapid genomic testing before becoming a historical ticker. Its business centered on helping clinicians identify pathogens and resistance faster.
Geographic Base and Sector Classification
OpGen was headquartered in the United States and traded on NASDAQ. It sat in diagnostics and molecular testing.
Business Model Characteristics
The company depended on test adoption, commercialization, and hospital workflow integration. Investors historically watched revenue, reimbursement, and operational execution.
Position Within the Biotechnology Landscape
OpGen belongs to the historical diagnostics infrastructure category. It is not a drug stock, but it supported the testing ecosystem that informs patient care.
Future catalysts
OpGen is a legacy / closeout story, so the catalysts are any final strategic or asset-resolution update rather than a live diagnostic milestone. The market is focused on residual value.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does OpGen do?
OpGen was a molecular diagnostics company focused on infectious disease and rapid genomic testing before becoming a historical ticker. Its business centered on helping clinicians identify pathogens and resistance faster.
On which exchange is OPGN stock listed?
OpGen (OPGN) is associated with NASDAQ, United States, Biopharma.
What is OpGen?
OpGen is a legacy / closeout story, so the catalysts are any final strategic or asset-resolution update rather than a live diagnostic milestone.
Which conditions is OpGen targeting with OpGen?
OpGen is a legacy / closeout story, so the catalysts are any final strategic or asset-resolution update rather than a live diagnostic milestone.
How does OpGen describe recent progress with OpGen?
OpGen is a legacy / closeout story, so the catalysts are any final strategic or asset-resolution update rather than a live diagnostic milestone.
What future catalysts are investors watching for OpGen?
OpGen is a legacy / closeout story, so the catalysts are any final strategic or asset-resolution update rather than a live diagnostic milestone. The market is focused on residual value.